Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

Completed · Phase 2 · Has a placebo group

Conditions studied: Schizophrenia

In brief

The purpose of this research study is to determine whether a short-term administration of an investigational study drug may provide evidence of improvement in cognitive functioning in a group of stable male subjects with schizophrenia.

Key facts

Study ID

NCT00129441

Run by

University of Pittsburgh

People needed

16

Starts

2005-08-01

Expected to finish

2008-01-01

Last updated by the study team

2011-10-17

Who can join

Age: 18 and older, up to 50. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male participants
• Between the ages of 18 and 50
• Meet diagnostic criteria for schizophrenia or schizoaffective disorder
• Are clinically stable for a minimum of 3 months on current dose of medication
• Are unemployed (i.e., work less than 20 hours per week at competitive employment)

You may not qualify if…

• Psychoactive substance dependence within the past 6 months or substance abuse within the past month
• History of head trauma or other neurological disorder
• Medical illness or medications, such as benzodiazepine treatment or HIV medications, that may be affected by study participation (the study doctor will discuss this with potential subjects)
• Mental retardation
• Seizure disorder
• History of a heart attack, arrhythmia, or other heart disease

Where it is running

• University of Pittsburgh — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.